Predictors of response to interferon therapy

Area of Science:

• Hepatology
• Virology
• Pharmacology

Background:

• Interferon (IFN) therapy is a primary treatment for hepatitis C virus (HCV) infection.
• Treatment duration and baseline patient factors significantly influence sustained virologic response (SVR).
• Understanding predictors of response is crucial for optimizing HCV treatment strategies.

Purpose of the Study:

• To review the key factors influencing sustained responses to interferon therapy in patients with HCV.
• To identify baseline characteristics that predict treatment efficacy and long-term outcomes.
• To inform clinical decision-making regarding individualized HCV treatment regimens.

Main Methods:

• Review of existing evidence on interferon therapy for HCV.
• Analysis of factors including treatment duration, viral load, HCV genotype, and disease severity.
• Evaluation of viral diversity and its impact on treatment response.

Main Results:

• Prolonged IFN therapy (≥12 months) is associated with higher sustained response rates.
• Low baseline viremia and lower HCV quasispecies diversity predict better long-term response.
• HCV genotypes 2 and 3 respond better than genotype 1; cirrhotic patients require cautious treatment due to risks.
• Mild disease severity correlates with higher sustained response rates compared to cirrhosis.

Conclusions:

• Optimal treatment schedules and patient selection are critical for maximizing sustained responses to IFN therapy.
• Baseline factors like viral load, genotype, and disease stage provide valuable predictive information but should not exclude patients.
• Individualized treatment decisions, considering patient characteristics, are essential for effective HCV management.